Shares of Dynavax Technologies Corp. (NASDAQ: DVAX) saw a handy gain early on Wednesday after the company announced that it received a recommendation from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).
Essentially the ACIP voted unanimously in favor of including Heplisav-B on its list of recommended products for use to vaccinate adults against hepatitis B. Heplisav-B was approved by the U.S. Food and Drug Administration (FDA) in November 2017 for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Ultimately, the receipt of the ACIP recommendation is a key step in providing patients with broad access to Heplisav-B. Medical policies of many insurance plans and institutions require ACIP recommendation before a vaccine is covered or available to their patients.
Dynavax commercially launched Heplisav-B in the United States in January 2018, and it announced Tuesday that the field sales team will begin actively selling Heplisav-B next week.
Eddie Gray, CEO of Dynavax, commented:
With the ACIP’s recommendation, HEPLISAV-B has cleared an important milestone needed to position Dynavax to meet our long-term commercial goals. Additionally, this recognition emphasizes the important role of HEPLISAV-B in the prevention of hepatitis B infection in adults, reinforcing our belief that our unique two-dose vaccine with demonstrated higher rates of protection versus ENGERIX-B, and a safety profile similar to three-dose vaccines, will become the new standard of care for adults.
Shares of Dynavax were last seen up about 2% at $17.65 on Wednesday, with a consensus analyst price target of $29.00 and a 52-week range of $3.90 to $24.45.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.